HT Immunogenicity Report
The EpiMatrix High Throughput Immunogenicity Prediction Report gives an overall assessment of potential clinical immunogenicity for large sets of biologic candidates.
The HT analysis is valuable for comparing the immunogenic potential of a large set of proteins or antibody-derived sequences and acts as a mechanism for identifying the best lead candidate(s) to bring forward into development. The analysis is performed by immunoinformatics experts at EpiVax using the in silico tools of the ISPRI platform.
Using the EpiMatrix T cell epitope mapping system, we have developed an interactive in silico screening and optimization platform that evaluates the overall immunogenic potential of a biologic as well as identifies individual T cell epitope clusters contributing to its immunogenicity. In contrast to other immunogenicity prediction tools, our platform considers the contribution of regulatory T cell epitopes (‘Tregitopes’) to immunogenic potential. Tregitopes are highly conserved T cell epitopes derived from IgG that we and others have shown activate regulatory T cells and promote tolerance induction to associated antigens.
The allele-specific findings are summarized to produce an immunogenicity score for each input sequence, representing the overall immunogenic potential of the candidate. For antibody candidates, the ADA response of each input antibody is estimated and compared alongside a panel of licensed antibodies as well. After compiling this data, all candidates are ranked on an immunogenicity scale. The results are delivered in a final tabulated report including visual aids detailing the findings with respect to the immunogenicity of each sequence provided.
If you are interested in a highly detailed report that encompasses overall and regional immunogenicity (specifically identifies high affinity epitopes across multiple alleles) then you need a PreDeFT Report.